13 PBAC submissions on file, active 2005–2019. 62% have been recommended.
Submissions
13
2005 → 2019
Win rate
62 %
8 recommended of 13 bucketable
Drugs
8 · 6 listed
unique molecules submitted
PBS spend captured
—
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
1×Insufficient evidence of benefit in terms of survival gain or quality of life improvements in the broader population (high-grade malignant gliomas beyond GBM)
1×numbers of Grade III glioma patients too small to draw conclusions
1×Grade III glioma patients have better prognosis than GBM and would require demonstration of improved quality of life
1×Rule of Rescue does not apply as other treatment options available
1×uncertain clinical effectiveness resulting from the lack of a common reference